<table><tr><td>2</td><td>The amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;</td><td>-</td><td>-</td><td>-</td></tr><tr><td>3</td><td>The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;</td><td>-</td><td>-</td><td>-</td></tr><tr><td>4</td><td>The amount of interest accrued and remaining unpaid at the end of each accounting year; and</td><td>6.16</td><td>-</td><td>-</td></tr><tr><td>5</td><td>The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006.</td><td>-</td><td>-</td><td>-</td></tr></table>

23. During the immediately preceding five years, the company has not issued any bonus equity shares.

24. The Company's primary business includes Manufacturing and Trading into Biochemistry Reagents, Instruments and Consumables and accordingly segment disclosure has been disclosed.

25. No dividend were declared and paid by the company during the restated period.

26. Basis of Goodwill and its calculation on acquisition of subsidiary Q-line Innovation Pvt Ltd as on the date of 07th March, 2025 is given below

<table><thead><tr><td>Particulars</td><td>Amount (Rs In Lakhs)</td></tr></thead><tbody><tr><td>Value of the Net Assets as on the date of Acquisition</td><td>(26.16)</td></tr><tr><td>Consideration Paid</td><td>0.70</td></tr><tr><td>Goodwill on Acquisition</td><td>26.86</td></tr></tbody></table>

27. Figures have been rounded off to the multiple of lakhs. Previous year's figures have been regrouped, recast and rearranged wherever necessary to make them comparable with the current Period/year figures.

As per our consolidated report of even date

For R K Jagetiya & Co
Chartered Accountants
FRN 146264W

FOR AND ON BEHALF OF THE BOARD
Q- Line Biotech Limited

Saurabh Garg
Managing Director & CHAIRMAN
DIN: 02891621

Amita Garg
Whole-Time Director
DIN: 02891610

(CA Ravi K Jagetiya)
M. No. 134691
Proprietor
Date: 24th September, 2025
Place: Mumbai
UDIN-: 25134691BMGTLA9821

Akhand Pratap Singh
Company Secretary
PAN: CFRPS7649R
Date: 24th September, 2025
Place: Lucknow

Meenal Gupta
Chief Financial Officer
PAN -:ABHPG6642E